Alzheimer’s Therapeutic Research Institute
About the Institute
The Alzheimer’s Therapeutic Research Institute (ATRI) of the Keck School of Medicine of USC is an academic institute comprised of an unmatched group of expert scientific collaborators committed to advancing the development of new treatments for Alzheimer’s disease (AD) through innovation in clinical trials.
Located in San Diego, the institute is an integral part of the Keck School of Medicine of USC’s mission to create a leading hub of basic, translational and clinical research in neuroscience and neurological diseases by collaborating with sites and investigators around the world. USC ATRI promotes extensive collaboration and data sharing across academia, industry, regulators and advocacy groups with a focus on training future leaders in AD clinical research.
USC ATRI is funded by the National Institutes of Health (NIH), the Alzheimer’s Association, the Department of Defense, the pharmaceutical partners and advocacy groups to develop novel methods and engage in all phases of AD clinical trials as well as observational studies. Bringing broad expertise to a comprehensive array of partners, USC ATRI manages a portfolio of national and international multi-site studies.
Learn more about ATRI
New Alzheimer’s study aims to delay or prevent symptomsThe international trial co-managed by USC will test a drug in people who show no symptoms of the disease USC researchers announced Tuesday they will test a promising drug aimed at preventing or delaying the symptoms of Alzheimer’s disease. The international study, jointly managed by the USC Alzheimer’s Therapeutic Research Institute (ATRI) and Janssen Research & Development, will
12/08/2016 - 12/10/2016
Marriott Marquis San Diego Marina, 323 West Harbor Drive, San Diego, CA
View All ATRI Events